{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:18:19Z","timestamp":1789532299801,"version":"build-2803163510"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Saf. Regul."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Sarcoidosis is a multisystemic granulomatous disease of unknown origin and unpredictable cause, characterized by a dysregulated immune response. If histopathological hallmark is represented by the presence of non-caseating granulomas, clinical manifestations are variable and symptoms are not specific, and they depend on organs affected. Although thoracic involvement (lung and mediastinum) is the most common clinical manifestation, any organ can be virtually affected.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This paper is structured as a narrative review. A literature search was performed in four electronic databases (Pubmed, Cochrane, Scopus, and Ovid Medline) and Google from inception until February 2023 for relevant studies, meta-analyses, and reviews on corticosteroids\u2019 adverse events in sarcoidosis. English language only papers were included.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Although antimetabolites (such as Methotrexate) and immunosuppressant agents can be used as alternative therapy in refractory cases, traditionally systemic glucocorticoids represent the first choice for sarcoidosis treatment. However, their use is still debated, due to potential adverse effects, leading to a wide spectrum of complications particularly in patients who required long-term therapy. Hence, this article aims to provide a comprehensive updated review on the safety profile of glucocorticoid treatment in patients with sarcoidosis and their systemic effects.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> corticosteroids remain the first choice in Sarcoidosis, however, due to numerous side effects, dose and duration of treatment should be carefully adjusted and monitored by clinicians.<\/jats:p>","DOI":"10.3389\/fdsfr.2023.1319931","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T13:49:08Z","timestamp":1702561748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of corticosteroid therapy in sarcoidosis treatment"],"prefix":"10.3389","volume":"3","author":[{"given":"Alessandro","family":"Di Marco Berardino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zuccatosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","article-title":"Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink","volume":"61","author":"Abtahi","year":"2022","journal-title":"Rheumatol. Oxf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000441-200301000-00001","article-title":"Glucocorticoid-induced osteoporosis in patients with sarcoidosis","volume":"325","author":"Adler","year":"","journal-title":"Am. J. Med. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1378\/chest.123.6.2012","article-title":"Osteoporosis in pulmonary clinic patients: does point-of-care screening predict central dual-energy X-ray absorptiometry?","volume":"123","author":"Adler","year":"","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e000569","DOI":"10.1136\/bmjpo-2019-000569","article-title":"Adrenal suppression from glucocorticoids: preventing an iatrogenic cause of morbidity and mortality in children","volume":"3","author":"Ahmet","year":"2019","journal-title":"BMJ Paediatr. Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1479972316661926","article-title":"Managing fatigue in sarcoidosis - a systematic review of the evidence","volume":"14","author":"Atkins","year":"2017","journal-title":"Chron. Respir. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J. Bone Min. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/MCP.0000000000000501","article-title":"Nutrition and corticosteroids in the treatment of sarcoidosis","volume":"24","author":"Bast","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00128071-200809030-00003","article-title":"Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems","volume":"9","author":"Baughman","year":"2008","journal-title":"Am. J. Clin. Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.36141\/svdld.v34i4.6957","article-title":"The indications for the treatment of sarcoidosis: wells Law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1080\/17476348.2021.1932471","article-title":"Association between sarcoidosis and diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"Benmelouka","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/ki.1996.346","article-title":"ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease","volume":"50","author":"Berg","year":"1996","journal-title":"Kidney Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/crj.12098","article-title":"Relationship between parenchymal involvement and obstructive sleep apnea in subjects with sarcoidosis","volume":"9","author":"Bingol","year":"2015","journal-title":"Clin. Respir. J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00198-014-2870-7","article-title":"Bone density is normal and does not change over 2 years in sarcoidosis","volume":"26","author":"Bolland","year":"2015","journal-title":"Osteoporos. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1378\/chest.14-1475","article-title":"Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies","volume":"147","author":"Bonifazi","year":"2015","journal-title":"Chest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/mcp.0000000000000806","article-title":"Sarcoidosis and maligancy: the chicken and the egg?","volume":"27","author":"Bonifazi","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.7326\/0003-4819-119-12-199312150-00007","article-title":"Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann. Intern Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00198-015-3426-1","article-title":"Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort","volume":"27","author":"Bours","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00408-017-0076-4","article-title":"The burden of comorbidity and complexity in sarcoidosis: impact of associated chronic diseases","volume":"196","author":"Brito-Zeron","year":"2018","journal-title":"Lung"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1026028","DOI":"10.3389\/fmed.2022.1026028","article-title":"Bone fragility and sarcoidosis: an underestimated relationship","volume":"9","author":"Caffarelli","year":"2022","journal-title":"Front. Med. (Lausanne)."},{"key":"B22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.14309\/ajg.0000000000002024","article-title":"Sarcoidosis of the esophagus","volume":"118","author":"Cho","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MCP.0b013e32832d0403","article-title":"Fatigue in sarcoidosis: a systematic review","volume":"15","author":"de Kleijn","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s2213-2600(21)00311-8","article-title":"Misconceptions regarding symptoms of sarcoidosis","volume":"9","author":"Drent","year":"","journal-title":"Lancet Respir. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/nejmra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/mcp.0000000000000889","article-title":"Drug-induced comorbidities in patients with sarcoidosis","volume":"28","author":"Drent","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur. Respir. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00408-020-00323-8","article-title":"Ranking self-reported gastrointestinal side effects of pharmacotherapy in sarcoidosis","volume":"198","author":"Drent","year":"2020","journal-title":"Lung"},{"key":"B33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000029523","article-title":"Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis","volume":"67","author":"Drent","year":"2000","journal-title":"Respiration"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1183\/23120541.00028-2021","article-title":"Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids","author":"Entrop","year":"2021","journal-title":"ERJ Open Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e4928","DOI":"10.1136\/bmj.e4928","article-title":"Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study","volume":"345","author":"Fardet","year":"2012","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.4187\/respcare.02080","article-title":"Factors associated with fatigue in sarcoidosis","volume":"59","author":"Fleischer","year":"2014","journal-title":"Respir. Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/eurheartj\/ehab067","article-title":"Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factor","volume":"42","author":"Galiuto","year":"2021","journal-title":"Eur. Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e4279","DOI":"10.1097\/md.0000000000004279","article-title":"Digestive-tract sarcoidosis: French nationwide case-control study of 25 cases","volume":"95","author":"Ghrenassia","year":"2016","journal-title":"Med. Baltim."},{"key":"B41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.12703\/b\/9-14","article-title":"The role of vitamin D in sarcoidosis","volume":"9","author":"Gianella","year":"2020","journal-title":"Fac. Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40264-021-01045-3","article-title":"Adverse drug reactions from real-world data in inflammatory bowel disease patients in the IBDREAM Registry","volume":"44","author":"Giraud","year":"2021","journal-title":"Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/ph14050487","article-title":"The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug-drug interactions: drug-gene, drug-gene-gene and drug-drug-gene interactions","volume":"14","author":"Hahn","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1164\/rccm.201906-1250OC","article-title":"Income and other contributors to poor outcomes in U.S. Patients with sarcoidosis","volume":"201","author":"Harper","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"117954412110724","DOI":"10.1177\/11795441211072475","article-title":"Musculoskeletal manifestations of sarcoidosis","volume":"15","author":"Hasbani","year":"2022","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"B46","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00198-007-0513-y","article-title":"Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study","volume":"19","author":"Heijckmann","year":"2008","journal-title":"Osteoporos. Int."},{"key":"B47","first-page":"51","article-title":"Bone turnover and hip bone mineral density in patients with sarcoidosis","volume":"24","author":"Heijckmann","year":"2007","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study","author":"Hendriks","year":"2018","journal-title":"Respir. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/rmed.2000.0916","article-title":"Correlates of osteoporosis in chronic obstructive pulmonary disease","volume":"94","author":"Incalzi","year":"2000","journal-title":"Respir. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.rdc.2015.08.012","article-title":"Corticosteroids in sarcoidosis","volume":"42","author":"Judson","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B51","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","article-title":"The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis","volume":"109","author":"Judson","year":"2015","journal-title":"Respir. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ni.2343","article-title":"Immunological complications of obesity","volume":"13","author":"Kanneganti","year":"2012","journal-title":"Nat. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000107621","article-title":"Dermatoporosis: a chronic cutaneous insufficiency\/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments","volume":"215","author":"Kaya","year":"2007","journal-title":"Dermatology"},{"key":"B54","first-page":"1264","article-title":"Lipid profiles in patients with systemic lupus erythematosus","volume":"21","author":"Leong","year":"1994","journal-title":"J. Rheumatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s41030-021-00160-x","article-title":"A comprehensive review of sarcoidosis treatment for pulmonologists","volume":"7","author":"Melani","year":"2021","journal-title":"Pulm. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s40520-022-02261-2","article-title":"Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: this manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF)","volume":"34","author":"Messina","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00198-017-4115-z","article-title":"Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis","volume":"28","author":"Oshagbemi","year":"2017","journal-title":"Osteoporos. Int."},{"key":"B59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1378\/chest.12-1524","article-title":"Excessive daytime sleepiness and obstructive sleep apnea in patients with sarcoidosis","volume":"143","author":"Patterson","year":"2013","journal-title":"Chest"},{"key":"B61","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/00007611-200406000-00016","article-title":"Renal failure and hypercalcemia as initial manifestations of extrapulmonary sarcoidosis","volume":"97","author":"Ponce","year":"2004","journal-title":"South Med. J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1136\/jcp.46.12.1089","article-title":"Effects of single dose compared with three days' prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets","volume":"46","author":"Pountain","year":"1993","journal-title":"J. Clin. Pathol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1003432","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-2007-1006290","article-title":"Bone mineral content in sarcoidosis","volume":"13","author":"Rizzato","year":"1992","journal-title":"Semin. Respir. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamadermatol.2013.60","article-title":"Reliability and convergent validity of the cutaneous sarcoidosis activity and Morphology instrument for assessing cutaneous sarcoidosis","volume":"149","author":"Rosenbach","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"106624","DOI":"10.1016\/j.rmed.2021.106624","article-title":"Risk of acute myocardial infarction in sarcoidosis: a population-based cohort study from Sweden","volume":"188","author":"Rossides","year":"2021","journal-title":"Respir. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/heartjnl-2021-319129","article-title":"Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden","volume":"108","author":"Rossides","year":"2022","journal-title":"Heart"},{"key":"B68","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar4519","article-title":"Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients","volume":"16","author":"Saidenberg-Kermanac'h","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Schacke","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.tem.2012.05.011","article-title":"Adipose tissue-resident immune cells: key players in immunometabolism","volume":"23","author":"Schipper","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000236781","article-title":"Glucocorticoid-induced apoptosis of lymphoid cells","volume":"105","author":"Schwartzman","year":"1994","journal-title":"Int. Arch. Allergy Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"323","DOI":"10.15403\/jgld-4122","article-title":"Management of hepatic sarcoidosis","volume":"31","author":"Sollors","year":"2022","journal-title":"J. Gastrointestin Liver Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11926-011-0170-1","article-title":"Bone health issues in sarcoidosis","volume":"13","author":"Sweiss","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1080\/07853890.2022.2063375","article-title":"Comorbidities of sarcoidosis","volume":"54","author":"Tana","year":"2022","journal-title":"Ann. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment","volume":"37","author":"Tebben","year":"2016","journal-title":"Endocr. Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"B77","first-page":"61","article-title":"Sleep apnea in sarcoidosis","volume":"14","author":"Turner","year":"1997","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00198-017-3962-y","article-title":"Risk of fragility fracture among patients with sarcoidosis: a population-based study 1976-2013","volume":"28","author":"Ungprasert","year":"","journal-title":"Osteoporos. Int."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1601290","DOI":"10.1183\/13993003.01290-2016","article-title":"Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013","volume":"49","author":"Ungprasert","year":"","journal-title":"Eur. Respir. J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Min. Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11083-004-3716-2","article-title":"Sleep disturbances associated with periodic leg movements in chronic sarcoidosis","volume":"21","author":"Verbraecken","year":"2004","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1378\/chest.129.5.1234","article-title":"A new tool to assess sarcoidosis severity","volume":"129","author":"Wasfi","year":"2006","journal-title":"Chest"},{"key":"B83","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jacc.2020.06.038","article-title":"Long-term adverse cardiac outcomes in patients with sarcoidosis","volume":"76","author":"Yafasova","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5606\/ArchRheumatol.2019.6883","article-title":"Bone mineral loss and fracture in sarcoidosis: a systematic review and meta-analysis","volume":"34","author":"Yong","year":"2019","journal-title":"Arch. Rheumatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e33442","DOI":"10.1371\/journal.pone.0033442","article-title":"Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden","volume":"7","author":"Zoller","year":"2012","journal-title":"PLoS One"}],"container-title":["Frontiers in Drug Safety and Regulation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2023.1319931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T16:42:07Z","timestamp":1732552927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdsfr.2023.1319931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":85,"alternative-id":["10.3389\/fdsfr.2023.1319931"],"URL":"https:\/\/doi.org\/10.3389\/fdsfr.2023.1319931","relation":{},"ISSN":["2674-0869"],"issn-type":[{"value":"2674-0869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"article-number":"1319931"}}